Financial reports
ARS
2023 FY
Annual report to shareholders
5 Apr 24
10-Q
2024 Q1
Quarterly report
9 Feb 24
10-K
2023 FY
Annual report
15 Dec 23
10-Q
2023 Q3
Quarterly report
9 Aug 23
10-Q
2023 Q2
Quarterly report
11 May 23
ARS
2022 FY
Annual report to shareholders
7 Apr 23
10-K/A
2022 FY
Annual report (amended)
27 Mar 23
10-Q
2023 Q1
Quarterly report
10 Feb 23
10-K
2022 FY
Annual report
16 Dec 22
10-Q
2022 Q3
Quarterly report
12 Aug 22
Current reports
8-K
Edesa Biotech Reports Fiscal 1st Quarter 2024 Results
9 Feb 24
8-K
Edesa Biotech Reports Fiscal Year 2023 Results
15 Dec 23
8-K
Other Events
26 Oct 23
8-K
Entry into a Material Definitive Agreement
23 Oct 23
8-K
Edesa Biotech to Receive Up To C$23 Million in Funding from Federal Government
12 Oct 23
8-K
Edesa Biotech Announces One-for-Seven Reverse Share Split
11 Oct 23
8-K
Edesa Biotech Reports Fiscal Third Quarter 2023 Results
9 Aug 23
8-K
Edesa Biotech Appoints Biotech Deal Veteran to CFO Role
27 Jun 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
23 Jun 23
8-K
Departure of Directors or Certain Officers
24 May 23
Registration and prospectus
S-8
Registration of securities for employees
24 May 23
424B5
Prospectus supplement for primary offering
27 Mar 23
424B3
Prospectus supplement
23 Dec 22
S-3
Shelf registration
16 Dec 22
S-3
Shelf registration
5 Aug 22
424B4
Prospectus supplement with pricing info
19 Apr 22
S-1
IPO registration
11 Apr 22
D
Indefinite amount in options / securities to be acquired, 1 investor
5 Apr 22
424B5
Prospectus supplement for primary offering
23 Mar 22
424B5
Prospectus supplement for primary offering
4 Mar 22
Proxies
DEFA14A
Additional proxy soliciting materials
5 Apr 24
DEF 14A
Definitive proxy
5 Apr 24
DEF 14A
Definitive proxy
28 Mar 23
DEF 14A
Definitive proxy
1 Apr 22
DEF 14A
Definitive proxy
3 Mar 21
DEFA14A
Additional proxy soliciting materials
24 Mar 20
DEF 14A
Definitive proxy
23 Mar 20
DEF 14C
Information statement
25 Oct 19
DEFA14A
Additional proxy soliciting materials
8 May 19
DEFM14A
Proxy related to merger
18 Apr 19
Other
EFFECT
Notice of effectiveness
27 Dec 22
CORRESP
Correspondence with SEC
21 Dec 22
UPLOAD
Letter from SEC
21 Dec 22
EFFECT
Notice of effectiveness
15 Aug 22
CORRESP
Correspondence with SEC
10 Aug 22
UPLOAD
Letter from SEC
9 Aug 22
EFFECT
Notice of effectiveness
20 Apr 22
CORRESP
Correspondence with SEC
15 Apr 22
UPLOAD
Letter from SEC
15 Apr 22
EFFECT
Notice of effectiveness
9 Mar 20
Ownership
4
Pardeep Nijhawan
2 Apr 24
4
Pardeep Nijhawan
25 Mar 24
4
Pardeep Nijhawan
1 Mar 24
4
Pardeep Nijhawan
2 Feb 24
SC 13G/A
Velan Capital Investment Management LP
29 Jan 24
SC 13D/A
Pardeep Nijhawan Medicine Professional Corp
16 Jan 24
4
Pardeep Nijhawan
12 Jan 24
SC 13D/A
Pardeep Nijhawan Medicine Professional Corp
21 Aug 23
4
Stephen Lemieux
4 Aug 23
4
Michael J Brooks
4 Aug 23